Indoline-sulfonamides compounds
    3.
    发明申请
    Indoline-sulfonamides compounds 失效
    二氢吲哚磺酰胺化合物

    公开(公告)号:US20080058386A1

    公开(公告)日:2008-03-06

    申请号:US11798079

    申请日:2007-05-10

    摘要: A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R″—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R′ and R″ independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

    摘要翻译: 公开了一系列二氢吲哚磺酰胺化合物。 二氢吲哚磺酰胺化合物的配方如式(I)所示。 在式(I)中,R 1是H或卤素; R 2是Ar,Ar-C(O) - ,Ar-CH 2 - ,Ar-SO 2 - ,Ar-OC( O)或R“C(O) - ,Ar是取代或未取代的C 5 -C 20芳基,环基,杂环基或杂芳基,R'和R”独立地是C 1 -C 10烷基或C 1 -C 10 烷氧基 R 3是C 5 -C 15芳基或C 1 -C 10烷基。 本发明中公开的二氢吲哚磺酰胺化合物的特征在于抑制微管蛋白聚合,并用合适的药学上可接受的载体处理癌症和其它微管蛋白聚合相关疾病。